NeoGenomics appoints Jeffrey S. Sherman as CFO; William Bonello steps down

NEOGENOMICS INC

Jeffrey S. Sherman named CFO effective Dec 7, 2022; William Bonello remains as employee for transition support.
Base salary $525,000; annual target bonus 70% of salary; sign-on cash $250,000; sign-on equity $3,000,000 (RSUs and options).
Sherman has 32 years healthcare finance experience, previously CFO at Privia Health, HMS, AccentCare, Lifepoint Hospitals.
Sherman led the sale of HMS to Veritas-backed Gainwell Technologies for $3.4 billion in April 2021.
CEO Chris Smith highlights Sherman's skills in pricing, revenue cycle management to return NeoGenomics to profitable growth.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeffrey S. Sherman

Chief Financial Officer

NEO · NEOGENOMICS INC

Effective: 2022-12-07
Filed: December 6, 2022, 6:59 PM ET

On December 5, 2022, the Company appointed Jeffrey S. Sherman, age 57, as Chief Financial Officer of the Company, effective December 7, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jeffrey S. Sherman was appointed as Chief Financial Officer at NEOGENOMICS INC.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On December 5, 2022, the Company appointed Jeffrey S. Sherman, age 57, as Chief Financial Officer of the Company, effective December 7, 2022

View on SEC.gov

NEOGENOMICS INC filing history →

Source: SEC EDGAR

accession 0001077183-22-000197

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.